Alexion Pharmaceuticals has successfully acquired two new drug approvals that will expand its revenue base beyond its flagship drug Soliris, but analysts are showing little confidence in the underwhelming launches.
The ultra-rare disease company announced earnings Feb 3, admitting that the launches of its two recently-approved drugs, Strensiq (asfotase alfa)...
The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.
